Aramark

NYSE:ARMK Voorraadrapport

Marktkapitalisatie: US$11.8b

Aramark Toekomstige groei

Future criteriumcontroles 2/6

Aramark zal naar verwachting groeien in winst en omzet met respectievelijk 17.8% en 5.9% per jaar. De winst per aandeel zal naar verwachting groeien met 17.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.1% zijn.

Belangrijke informatie

17.8%

Groei van de winst

17.79%

Groei van de winst per aandeel

Hospitality winstgroei18.1%
Inkomstengroei5.9%
Toekomstig rendement op eigen vermogen17.13%
Dekking van analisten

Good

Laatst bijgewerkt27 Apr 2026

Recente toekomstige groei-updates

Analyse-artikel Nov 20

Earnings Miss: Aramark Missed EPS By 19% And Analysts Are Revising Their Forecasts

Aramark ( NYSE:ARMK ) shareholders are probably feeling a little disappointed, since its shares fell 4.6% to US$36.73...

Recent updates

Analyse-update Apr 29

ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow

The analyst price target for Aramark is adjusted modestly higher to $47.63 from $47.16, with analysts pointing to steadier revenue growth assumptions, a slightly higher profit margin outlook, and recent positive research highlighting organic growth and new contract wins as support for the change. Analyst Commentary Recent research around Aramark centers on organic growth trends, contract wins and how these factors feed into valuation.
Analyse-update Apr 13

ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow

Aramark's analyst price target has inched higher, with a modest fair value adjustment to about $47.16 as analysts highlight stronger than expected organic growth trends, a new RWJ Barnabas Health contract scheduled to ramp up in 2026, and generally constructive sector views as key supports. Analyst Commentary Bullish analysts are generally constructive on Aramark, pointing to recent price target increases and renewed coverage with higher fair value estimates.
Analyse-update Mar 26

ARMK: New Contracts And Buybacks Will Support Future Free Cash Flow

Analysts have raised the implied fair value for Aramark by about $0.47 to $47.09, reflecting updated assumptions around revenue growth, profitability and future P/E in the context of a recent wave of higher $50 price targets across research reports. Analyst Commentary Recent research updates cluster around a US$50 price target, with several firms lifting their views in quick succession.
Seeking Alpha Mar 24

Aramark's Growth Story Isn't Over Yet

Summary Aramark is rated a "Buy" due to consistent revenue growth, attractive valuation, and strong execution in core food and facilities services. ARMK's revenue rose from $16.08 billion in 2023 to $18.51 billion in 2025, with 2026 guidance targeting $19.55–$19.95 billion and adjusted EPS of $2.18–$2.28. Business & Industry and international segments are key growth drivers, bolstered by refreshment services and technology investments like AI supply chain tools. While not a home run, ARMK's focused strategy, contract wins, and relative valuation make it a compelling prospect among peers. Read the full article on Seeking Alpha
Analyse-update Mar 05

ARMK: Contract Wins And Buybacks Will Support Higher FY26 Cash Generation

Narrative Update Analysts have lifted their average price target on Aramark by about $3 to $50, citing stronger than expected organic growth and increased visibility from a new RWJ Barnabas Health contract, as well as broader optimism regarding revenue, EPS and free cash flow trends into 2026. Analyst Commentary Recent Street research on Aramark centers on higher price targets and fresh coverage, with most of the discussion tied to organic growth trends, contract wins and expectations for earnings and cash flow through 2026.
Analyse-update Feb 18

ARMK: Contract Wins And Buybacks Will Support Stronger FY26 Earnings Delivery

Analysts have lifted their average Aramark price target from about $44.60 to roughly $46.63. The updated views factor in recent organic growth trends and expectations for future contract contributions and earnings power.
Analyse-update Feb 03

ARMK: Contract Timing Delays Will Support Stronger FY26 Earnings Delivery

Narrative Update on Aramark Analysts have trimmed their Aramark price target to US$44 from US$49, citing a shift in expected revenue timing as client driven delays in new contract starts across Corrections, Workplace Experience, and Healthcare push more of the projected contribution into FY26. They continue to model a similar long term P/E and margin profile.
Analyse-update Jan 19

ARMK: Contract Timing Delays Will Create FY26 Margin Upside Scenario

Analysts recently trimmed their Aramark price target to $44 from $49, pointing to what they describe as strong underlying business momentum, but also to client driven timing delays on new contract starts that are expected to shift some revenue and margin impact into FY26. Analyst Commentary Bullish Takeaways Bullish analysts see the lower US$44 price target as reflecting updated timing rather than a change in their view of Aramark’s underlying business momentum.
Analyse-artikel Jan 06

Is Aramark (NYSE:ARMK) Worth US$38.0 Based On Its Intrinsic Value?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Aramark fair value estimate is US$30.02 Current share price of...
Analyse-update Jan 04

ARMK: Delayed Contract Ramps Will Drive Stronger Earnings Setup In Fiscal 2026

Analysts have modestly reduced their price target on Aramark to approximately $44 from about $49, citing strong underlying business momentum but near term revenue and earnings pressure from client driven timing delays in new contract starts, which are now expected to shift more meaningfully into FY26. Analyst Commentary Bullish Takeaways Bullish analysts highlight that underlying business momentum remains solid across key operating segments, supporting confidence in the company’s long term growth trajectory despite near term volatility.
Analyse-update Dec 18

ARMK: Delayed Contract Starts Will Support Stronger Earnings Momentum In Fiscal 2026

Analysts have trimmed their price target on Aramark to $44 from $49, reflecting expectations for strong underlying momentum but a near term zig zag in revenue and margins as client driven contract start delays shift more growth into FY26. Analyst Commentary Street research indicates that the recent price target reduction reflects adjustments to the timing of expected growth rather than a reset of the long term thesis.
Analyse-update Dec 04

ARMK: Delayed Contract Starts Will Shift Earnings Momentum Toward Fiscal 2026

Analysts have modestly raised their Aramark price target to approximately $44.60 per share from about $44.43, citing strong underlying business momentum despite near term revenue and earnings pressure from client driven delays in new contract starts, which are now expected to shift growth into FY26. Analyst Commentary Recent Street research highlights a mixed, but generally constructive, view on Aramark, with analysts fine tuning their expectations to reflect both the strength of the core business and the impact of timing related revenue shifts.
Analyse-artikel Nov 20

Earnings Miss: Aramark Missed EPS By 19% And Analysts Are Revising Their Forecasts

Aramark ( NYSE:ARMK ) shareholders are probably feeling a little disappointed, since its shares fell 4.6% to US$36.73...
Analyse-update Nov 19

ARMK: Delayed Contract Starts Will Drive Revenue Expansion Beyond Fiscal 2025

Aramark's analyst price target has been revised downward from $45.10 to $44.43, as analysts factor in strong underlying business momentum while adjusting for delays in revenue and earnings due to client-driven timing in new contract starts. Analyst Commentary Analyst perspectives on Aramark reflect a mix of optimism about core business trends and caution around near-term uncertainty driven by client timing.
Analyse-artikel Oct 01

What Is Aramark's (NYSE:ARMK) Share Price Doing?

Aramark ( NYSE:ARMK ) saw significant share price movement during recent months on the NYSE, rising to highs of...
Analyse-update Sep 03

Sports, Education And Healthcare Wins Will Expand Global Reach

Aramark’s fair value estimate was slightly reduced as a result of a deteriorating net profit margin and an increased future P/E, indicating weaker profitability and pricier valuation. What's in the News Aramark expanded its presence in NCAA collegiate sports by delivering customized hospitality experiences at over 30 football stadiums and secured new partnerships with Arizona State University and the University of Nebraska.
Analyse-artikel Jul 07

Is Aramark (NYSE:ARMK) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analyse-artikel Jun 16

Is It Time To Consider Buying Aramark (NYSE:ARMK)?

Let's talk about the popular Aramark ( NYSE:ARMK ). The company's shares received a lot of attention from a substantial...
Seeking Alpha Apr 28

Aramark Is A 'BUY', But With Some Details (Rating Upgrade)

Summary I initially invested in Aramark, saw a 50%+ gain, then switched to Sodexo, which has shown potential for further growth. Despite Aramark's recent 14% decline, I see a long-term investment opportunity, especially with Sodexo's potential acquisition interest. Aramark's strong performance, revenue growth, and improved margins make it a compelling buy, with an updated price target of $40/share. While Aramark is a "BUY," Sodexo remains a superior choice due to better credit rating, yield, and overall fundamentals. Read the full article on Seeking Alpha
Seeking Alpha Feb 08

Aramark: Rating Downgrade To Hold As I See Risk To The Company Meeting FY25 Guidance

Summary I downgraded ARMK from buy to hold due to 1Q25 performance and risks of missing FY25 guidance. Weak US organic growth and onboarding delays in Education and Healthcare segments pose significant risks to achieving FY25 targets. Strong international growth is promising but may not offset US weaknesses and potential FX headwinds. ARMK's valuation could drop significantly if growth slows, with potential de-rating to low teens forward earnings multiple. Read the full article on Seeking Alpha
Seeking Alpha Nov 22

Aramark: Robust FY25 Outlook

Summary I reiterate a buy rating for ARMK due to its robust FY25 outlook, driven by organic growth and a strengthened balance sheet. Aramark's 4Q24 earnings were in line with expectations, with revenue growth driven by organic means and strong pipeline momentum. The launch of Avendra, ARMK's global GPO, is expected to enhance margins by leveraging scale for better purchasing deals. ARMK's improved balance sheet allows for increased shareholder returns through dividends and a $500 million share buyback program. Read the full article on Seeking Alpha
Seeking Alpha Sep 27

Aramark: Switching To Sodexo After M&A Talk

Summary I invested in Aramark and saw a 55% gain, outperforming the S&P500, despite initial skepticism from readers. ARMK's operational performance has improved, with revenue growth, margin improvements, and strategic liquidity enhancements, making it attractive to Sodexo. Despite the Company's gains, I believe it's overvalued now; Sodexo offers better value with a higher yield and lower debt. I'm rotating my investment from Aramark to Sodexo, targeting a more favorable valuation and higher quality for future growth. Read the full article on Seeking Alpha
User avatar
Nieuwe analyse Aug 25

Calculated Expansions And Efficiency Gains Propel Revenue And Profitability Forward

Aramark's focus on new client acquisition and retention promises enhanced revenue growth and improved profitability margins through strategic growth initiatives.
Seeking Alpha Jun 30

Aramark: Visible Path To Both Revenue And EBIT Growth

Summary Aramark has strong growth potential supported by volume and pricing power. The company operates in the contract catering industry, competing with Sodexo and Compass, and serves a wide range of verticals globally. Based on historical and peer performance, ARMK should be able to expand its margin. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NYSE:ARMK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
9/30/202822,3416956891,2949
9/30/202721,0316176231,19416
9/30/202619,8035075151,01716
1/2/202618,786317234726N/A
10/3/202518,506326432921N/A
6/27/202517,875362281767N/A
3/28/202517,624348371831N/A
12/27/202417,545340365796N/A
9/27/202417,401263299727N/A
6/28/202417,184248328741N/A
3/29/202416,861477207623N/A
12/29/202316,577438306717N/A
9/29/202316,083448383766N/A
6/30/202316,273415180566N/A
3/31/202316,348169144530N/A
12/30/202216,292190187591N/A
9/30/202213,68739383694N/A
7/1/202215,487154-132281N/A
4/1/202214,341146-126307N/A
12/31/202113,30033-143269N/A
10/1/202112,096-91249657N/A
7/2/202111,237-275111485N/A
4/2/202110,408-564137490N/A
1/1/202111,320-689-18371N/A
10/2/202012,830-462-242177N/A
6/26/202014,089-227240701N/A
3/27/202015,947112317804N/A
12/27/201916,216344N/A878N/A
9/27/201916,227449N/A984N/A
6/28/201916,190538N/A1,115N/A
3/29/201916,151528N/A1,119N/A
12/28/201816,090526N/A1,160N/A
9/28/201815,790568N/A1,052N/A
6/29/201815,530506N/A750N/A
3/30/201815,152498N/A647N/A
12/29/201714,834541N/A768N/A
9/29/201714,604374N/A1,053N/A
6/30/201714,494344N/A906N/A
3/31/201714,488324N/A1,044N/A
12/30/201614,441320N/A1,010N/A
9/30/201614,416288N/A867N/A
7/1/201614,418261N/A936N/A
4/1/201614,317250N/A856N/A
1/1/201614,337244N/A758N/A
10/2/201514,329236N/A802N/A
7/3/201514,731223N/A573N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ARMK ( 17.8% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van ARMK ( 17.8% per jaar) zal naar verwachting sneller groeien dan de US markt ( 16.7% per jaar).

Hoge groeiwinsten: De winst van ARMK zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van ARMK ( 5.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.6% per jaar).

Hoge groei-inkomsten: De omzet van ARMK ( 5.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ARMK zal naar verwachting over 3 jaar laag zijn ( 17.1 %).


Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/11 05:19
Aandelenkoers aan het einde van de dag2026/05/11 00:00
Inkomsten2026/01/02
Jaarlijkse inkomsten2025/10/03

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Aramark wordt gevolgd door 23 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Andrew WittmannBaird
Manav PatnaikBarclays
Stuart GordonBerenberg